The α-like RNA polymerase II core subunit 3 (RPB3) is involved in tissue-specific transcription and muscle differentiation via interaction with the myogenic factor myogenin

被引:25
作者
Corbi, N
Di Padova, M
De Angelis, R
Bruno, T
Libri, V
Iezzi, S
Floridi, A
Fanciulli, M
Passananti, C
机构
[1] CNR, Ist Tecnol Biomed, I-00137 Rome, Italy
[2] Regina Elena Inst Canc Res, Cell Metab & Pharmacokinet Lab, I-00158 Rome, Italy
[3] Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy
关键词
pol II subunits; doxorubicin; yeast two hybrid;
D O I
10.1096/fj.02-0123fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
RNA polymerase II core subunit 3 (RPB3) is an alpha-like core subunit of RNA polymerase II (pol II). It is selectively down-regulated upon treatment with doxorubicin (dox). Due to the failure of skeletal muscle cells to differentiate when exposed to dox, we hypothesized that RPB3 is involved in muscle differentiation. To this end, we have isolated human muscle RPB3-interacting proteins by using yeast two-hybrid screening. It is of interest that an interaction between RPB3 and the myogenic transcription factor myogenin was identified. This interaction involves a specific region of RPB3 protein that is not homologous to the prokaryotic alpha subunit. Although RPB3 contacts the basic helix-loop-helix (HLH) region of myogenin, it does not bind other HLH myogenic factors such as MyoD, Myf5, and MRF4. Coimmunoprecipitation experiments indicate that myogenin contacts the pol II complex and that the RPB3 subunit is responsible for this interaction. We show that RPB3 expression is regulated during muscle differentiation. Exogenous expression of RPB3 slightly promotes myogenin transactivation activity and muscle differentiation, whereas the region of RPB3 that contacts myogenin, when used as a dominant negative molecule (Sud), counteracts these effects. These results indicate for the first time that the RPB3 pol II subunit is involved in the regulation of tissue-specific transcription.
引用
收藏
页码:1639 / +
页数:22
相关论文
共 50 条
  • [1] SUBUNITS OF THE SCHIZOSACCHAROMYCES-POMBE RNA POLYMERASE-II - ENZYME-PURIFICATION AND STRUCTURE OF THE SUBUNIT 3 GENE
    AZUMA, Y
    YAMAGISHI, M
    ISHIHAMA, A
    [J]. NUCLEIC ACIDS RESEARCH, 1993, 21 (16) : 3749 - 3754
  • [2] Molecular distinction between specification and differentiation in the myogenic basic helix-loop-helix transcription factor family
    Bergstrom, DA
    Tapscott, SJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (07) : 2404 - 2412
  • [3] EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II:: Interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes
    Bertolotti, A
    Melot, T
    Acker, J
    Vigneron, M
    Delattre, O
    Tora, L
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (03) : 1489 - 1497
  • [4] Biesiada E, 1999, MOL CELL BIOL, V19, P2577
  • [5] Architecture of RNA polymerase II and implications for the transcription mechanism
    Cramer, P
    Bushnell, DA
    Fu, JH
    Gnatt, AL
    Maier-Davis, B
    Thompson, NE
    Burgess, RR
    Edwards, AM
    David, PR
    Kornberg, RD
    [J]. SCIENCE, 2000, 288 (5466) : 640 - 649
  • [6] MYOGENIN INDUCES THE MYOCYTE-SPECIFIC ENHANCER BINDING-FACTOR MEF-2 INDEPENDENTLY OF OTHER MUSCLE-SPECIFIC GENE-PRODUCTS
    CSERJESI, P
    OLSON, EN
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (10) : 4854 - 4862
  • [7] DOROSHOW JH, 1983, CANCER RES, V43, P4543
  • [8] The interacting RNA polymerase II subunits, hRPB11 and hRPB3, are coordinately expressed in adult human tissues and down-regulated by doxorubicin
    Fanciulli, M
    Bruno, T
    Di Padova, M
    De Angelis, R
    Lovari, S
    Floridi, A
    Passananti, C
    [J]. FEBS LETTERS, 1998, 427 (02) : 236 - 240
  • [9] Clotting of a novel human RNA polymerase II subunit downregulated by doxorubicin: New potential mechanisms of drug related toxicity
    Fanciulli, M
    Bruno, T
    Cerboni, C
    Bonetto, F
    Iacobini, C
    Frati, L
    Piccoli, M
    Floridi, A
    Santoni, A
    Punturieri, A
    [J]. FEBS LETTERS, 1996, 384 (01) : 48 - 52
  • [10] FORNARI FA, 1994, MOL PHARMACOL, V45, P649